Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 5, 2005, Pages 387-396

  Christensen, Palle Mark ^a   Brixen, Kim ^b   Gyrd Hansen, Dorte ^a   Kristiansen, Ivar Sønbø ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; VITAMIN D;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MODEL; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCANDINAVIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALENDRONATE; COHORT STUDIES; COST-BENEFIT ANALYSIS; DENMARK; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE;

POMACANTHUS MACULOSUS;

EID: 18744369610     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_08.x     Document Type: Article

References (70)

1. Advocaat, C. & E. Bautz-Holter: Prognose ett år etter hoftebrudd. [Prognosis One Year After Hip Fracture]. Tidsskr. Nor. Laegeforen. 1997, 117, 3801-3803.
2. Andersen, L., I. S. Kristiansen, J. A. Falch & I. Aursnes: Cost-effectiveness of alendronate for the prevention of osteoporotic fractures in Norwegian women. Working paper 11/1995. Statens Institutt for Folkehelse, 1995.
3. Ankjær-Jensen, A., E. T. Jacobsen & I. S. Thomsen: Rehabilitering af ældre med hoftebrud - omkostninger og effekt (DSI 94.08). Dansk Sygehus Institut. Copenhagen, 1994.
4. Ankjær-Jensen, A. & O. Johnell: Prevention of osteoporosis: Cost-effectiveness of different pharmaceutical treatments. Osteoporos Int. 1996, XX, 265-275.
5. Berglund-Roden, M., B. A. Swierstra, H. Wingstrand & K. G. Thorngren: Prospective comparison of hip fracture treatment. 856 cases followed for 4 months in the Netherlands and Sweden. Acta Orthop. Scand. 1994, 65, 287-294.
6. Black, D. M., S. R. Cummings, D. B. Karpf, J. A. Cauley, D. E. Thompson, M. C. Nevitt, D. C. Bauer, H. K. Genant, W. L. Haskell, R. Marcus, S. M. Ott, J. C. Torner, S. A. Quandt, T. F. Reiss & K. E. Ensrud: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996, 348, 1535-1541.
7. Brainsky, A., H. Glick, E. Lydick, R. Epstein, K. M. Fox, W. Hawkes, T. M. Kashner, S. I. Zimmerman & J. Magaziner: The economic cost of hip fractures in community-dwelling older adults: a prospective study. J. Am. Geriatr. Soc. 1997, 45, 281-287.
8. Brazier, J. E., C. Green & J. A. Kanis: A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int. 2002, 13, 768-776.
9. Browner, W. S., A. R. Pressman, M. C. Nevitt & S. R. Cummings: Mortality following fractures in older women. The study of osteoporotic fractures. Arch. Intern. Med. 1996, 156, 1521-1525.
10. Browner, W. S., D. G. Seeley, T. M. Vogt & S. R. Cummings. Non-trauma mortality in elderly women with low bone mineral density. Study of osteoporotic fractures research group. Lancet, 1991 338, 355-358.
11. Chapuy, M. C., M. E. Arlot, P. D. Delmas & P. J. Meunier: Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Brit. Med. J. 1994, 308, 1081-1082.
12. Chapuy, M. C. M. E. Arlot, F. Duboeuf, J. Brun, B. Crouzet, S. Arnaud, P. D. Delmas & P. J. Meunier: Vitamin D3 and calcium to prevent hip fractures in the elderly women. New Engl. J. Med. 1992, 327, 1637-1642.
13. Chrischilles, E., T. Shireman & R. Wallace: Costs and health effects of osteoporotic fractures. Bone 1994, 15, 377-386.
14. Christensen, P. M., K. Brixen & I. S. Kristiansen: Danish Osteoporosis Outcome Model (DOOM). A Technical Report. Health Economics Papers 2003:2 (Working Paper). Faculty of Social Sciences. University of Southern Denmark, 2003.
15. Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Amer. J. Med. 1993, 94, 646-650.
16. Cooper, C., E. J. Atkinson, S. J. Jacobsen, W. M. O'Fallon & L. J. Melton: Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 1993, 137, 1001-1005.
17. Cooper, C., E. J. Atkinson, W. M. O'Fallon & L. J. Melton: Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J. Bone Miner. Res. 1992, 7, 221-227.
18. Cserhati, P., K. Fekete, M. Berglund-Roden, H. Wingstrand & K. G. Thorngren: Hip fractures in Hungary and Sweden - differences in treatment and rehabilitation. Int. Orthop. 2002, 26, 222-228.
19. Cummings, S. R., D. M. Black, D. E. Thompson, W. B. Applegate, E. Barrett-Connor, T. A. Musliner, L. Palermo, R. Prineas, S. M. Rubin, J. C. Scott, T. Vogt, R. Wallace, A. Yates & A. Z. LaCroix: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998, 280, 2077-2082.
20. De Laet, C. E., B. A. van Hout, H. Burger, A. E. Weel, A. Hofman & H. A. Pols: Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int. 1999, 10, 66-72.
21. Dolan, P., D. Torgerson & T. K. Kakarlapudi: Health-related quality of life of colles' fracture patients. Osteoporos Int. 1999, 91, 196-199.
22. Eiskjaer, S., S. E. Ostgard, B. W. Jakobsen, J. Jensen & U. Lucht: Years of potential life lost after hip fracture among post-menopausal women. Acta Orthop. Scand. 1992, 63, 293-296.
23. Elmerson, S. & C. Zetterberg: Endast var fjarde patient i livet tio ar efter hoftfrakturoperation. [Only every fourth patient is alive 10 years after hip fracture surgery]. Läkartidningen 1989, 86, 1903-1904.
24. Ensrud, K. E., D. E. Thompson, J. A. Cauley, M. C. Nevitt, D. M. Kado, M. C. Hochberg, A. C. Santora & D. M. Black: Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture intervention trial research group. J. Amer. Geriatr. Soc. 2000, 48, 241-249.
25. Ettinger, B., D. M. Black, B. H. Mitlak, R. K. Knickerbocker, T. Nickelsen, H. K. Genant, C. Christiansen, P. D. Delmas, J. R. Zanchetta, J. Stakkestad, C. C. Gluer, K. Krueger, F. J. Cohen, S. Eckert, K. E. Ensrud, L. V. Avioli, P. Lips & S. R. Cummings: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized Clinical Trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1993, 282, 637-645.
26. Falch, J. A.: Epidemiology of fractures of the distal forearm in Oslo, Norway. Acta Orthop. Scand. 1983, 54, 291-295.
27. Falch, J. A. & H. E. Meyer: Dodelighet av larhalsbrudd. [Hip fracture mortality]. Tidsskr. Nor. Laegeforen. 1998, 118, 3674.
28. Finsen, V., M. Borset & I. Rossvoll: Mobility, survival and nursing-home requirements after hip fracture. Ann. Chir. Gynaecol. 1995, 84, 291-294.
29. Grady, D.: Postmenopausal hormons - therapy for symptoms only. New Engl. J. Med 2003, 348, 1835-1837.
30. Hawthorne, G., J. Richardson & N. A. Day: A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. Ann. Med. 2001, 33, 358-370.
31. Holmberg, S., R. Kalen & K. G. Thorngren: Treatment and outcome of femoral neck fractures. An analysis of 2418 patients admitted from their own homes. Clin. Orthop. 1987, 42-52.
32. Iglesias, C. P., D. J. Torgerson, A. Bearne & U. Böse: The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002, 95, 305-311.
33. Jensen, J. S. & E. Tondevold: Mortality after hip fractures. Acta Orthop. Scand. 1979, 50, 161-167.
34. Jensen, J. S., E. Tondevold & P. H. Sorensen: Social rehabilitation following hip fractures. Acta Orthop. Scand. 1979, 50, 777-785.
35. Johnell, O., B. Jonsson, L. Jonsson & D. Black: Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003, 21, 305-314.
36. Jonsson, B., J. Kanis, A. Dawson, A. Oden & O. Johnell: Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int. 1999, 10, 193-199.
37. Jönsson, L., F. Borgström & N. Zethraeus: Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the fracture intervention trial. Ugeskr. Lœger 2003, 165, 4112-4116.
38. Kanis, J. A. & B. Jonsson: Economic evaluation of interventions for osteoporosis. Osteoporos Int. 2002, 13, 765-767.
39. Kanis, J. A., A. Oden, O. Johnell, B. Jonsson, C. de Laet & A. Dawson: The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001, 12, 417-427.
40. Klotzbuecher, C. M., P. D. Ross, P. B. Landsman, T. A. Abbott & M. Berger: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J. Bone Miner. Res. 2000, 15, 721-739.
41. Kreutzfeldt, J., M. Haim & E. Bach: Hip fracture among the elderly in a mixed urban and rural population. Age Ageing 1984, 13, 111-119.
42. Krimsky, S.: Conflict of interest and cost-effectiveness analysis. JAMA 1999, 282, 1474-1475.
43. Larsen, J., P. M. Christensen & M. Andersen: Use of bisphosphonates 1993-1999 in Funen County, Denmark. A population based study. 18th International Conference on Pharmacoepidemiology, Edingburgh, August 18-21, 2002 (abstract).
44. Lofthus, C. M., E. K. Osnes, J. A. Falch, T. S. Kaastad, I. S. Kristiansen, L. Nordsletten I. Stensvold & H. E. Meyer: Epidemiology of hip fractures in Oslo, Norway. Bone 2001, 29, 413-418.
45. Looker, A. C., H. W. Wahner, W. L. Dunn, M. S. Calvo, T. B. Harris, S. P. Heyse, C.-C. J. Johnston & R. Lindsay R: Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998, 8, 468-489.
46. Lund, E.: Dodeligheten av fractura colli femoris i Norge 1980-94. [Mortality resulting from femoral neck fractures in Norway 1980-94]. Tidsskr. Nor. Laegeforen. 1998, 118, 2764-2766.
47. McClung, M. R., P. Geusens, P. D. Miller, H. Zippel, W. G. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, P. J. Meunier & J. Y. Reginster: Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. New Engl. J. Med. 2001, 344, 333-340.
48. Meyer, H. E., A. Tverdal, J. A. Falch & J. I. Pedersen: Factors associated with mortality after hip fracture. Osteoporos Int. 2000, 11, 228-232.
49. Neer, R. M., C. D. Arnaud, J. R. Zanchetta, R. Prince, G. A. Gaich, J. Y. Reginster, A. B. Hodsman, E. F. Eriksen, S. Ish-Shalom, H. K. Genant, O. Wang & B. H. Mitlak: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J. Med. 2001, 344, 434-1441.
50. Oleksik, A., P. Lips, A. Dawson, M. E. Minshall, W. Shen, C. Cooper & J. Kanis: Health-related quality of life in post-menopausal women with low BMD with or without prevalent vertebral fractures. J. Bone Miner. Res. 2000, 15, 1384-1392.
51. Pedersen, K. M., K. Wittrup-Jensen, R. Brooks & C. Gudex: Vœrdisœtning af sundhed. Teorien om kvalitetsjusterede leveår og en dansk anvendelse. Syddansk Universitetsforlag, 2003 (in Danish).
52. Poulsen, T. K., O. Ovesen, N. D. Röck, F. Andersen-Ranber, F. Møller-Larsen & J. Riis: Hip fractures in the county of Funen, Denmark. Incidences from 1973 ot 1978 compared with 1997 and 1998. 5th Congress of the European Federation of National Association of Orthopaedics and Traumatology, Rhodes-Greece, June 3-7: P137.
53. Ray, N. F., J. K. Chan, M. Thamer & L. J. Melton: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J. Bone Miner. Res. 1997, 12, 24-35.
54. Salkeld, G., I. D. Cameron, R. G. Cumming, S. Easter, J. Seymour, S. E. Kurrle & S. Quine: Quality of life related to fear of falling and hip fracture in older women: a time trade off study. Brit. Med. J. 2000, 320, 341-346.
55. Scott, A. M., C. Cormier, D. Hans, F. Favier, E. Hausherr, P. Dargent-Molina, P. D. Delmas, C. Ribot, J. L. Sebert, G. Breart & P. J. Meunier: How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS prospective study. Osteoporos Int. 1998, 8, 247-254.
56. Smith, R.: Beyond Conflict of Interest. Transparency Is the Key. BMJ 1998, 317, 291-292.
57. Solgaard, S. & V. S. Petersen: Epidemiology of distal radius fractures. Acta Orthop. Scand. 1985, 56, 391-393.
58. Stock, J. L., N. H. Bell, C. H. Chesnut, K. E. Ensrud, H. K. Genant, S. T. Harris, M. R. McClung, F. R. Singer, R. A. Yood, S. Pryor-Tillotson, L. Wei & A. C. Santora: Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Amer. J. Med. 1997, 103, 291-297.
59. Takstkatalog 2002, Odense University Hospital (http://www.ouh.dk/pubdb- soeg-patientinfo.asp?OpenDocument=fix&siidxxpubid= 3795). (accessed 20th December 2002) 2002 (in Danish).
60. Tidermark, J., N. Zethraeus, O. Svensson, H. Tornkvist & S. Ponzer: Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol. Qual. Life Res. 2002, 11, 473-481.
61. Tonino, R. P., P. J. Meunier, R. Emkey, J. A. Rodriguez-Portales, C. J. Menkes, R. D. Wasnich, H. G. Bone, A. C. Santora, M. Wu, R. Desai & P. D. Ross: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. J. Clin. Endocrinol Metab. 2000, 85, 3109-3115.
62. Tosteson, A. N., S. E. Gabriel, M. R. Grove, M. M. Moncur, T. S. Kneeland & L. J. Melton: Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001a, 12, 1042-1049.
63. Tosteson, A. N., B. Jonsson, D. T. Grima, B. J. O'Brien, D. M. Black & J. D. Adachi: Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions. Osteoporos Int. 2001b, 12, 849-857.
64. Wasnich, R. D.: Epidemiology and osteoporosis. In: Primer on the metabolic bone diseases of mineral metabolism, 4th. ed. Ed.: M. J. Favus. Lippincott Williams & Wilkins, 1999, pp. 257-259.
65. Weinstein, M. C., B. O'Brien, J. Hornberger, J. Jackson, M. Johannesson, C. McCabe & B. R. Luce: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - modeling studies. Value Health 2003, 6, 9-17.
66. Willis, M. S.: The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int. J. Technol Assess. Health Care 2002, 18, 791-807.
67. Zethraeus, N., W. Ben Sedrine, F. Caulin, S. Corcaud, H. J. Gathon, M. Haim, O. Johnell, B. Jonsson, J. A. Kanis, Y. Tsouderos & J. Y. Reginster: Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int. 2002a, 13, 841-857.
68. Zethraeus, N., F. Borgström, O. Johnell, J. Kanis, K. Önnby & B. Jonsson: Costs and quality of life associated with osteoporosis related fractures - results from a Swedish survey. SSE/EFI working paper series in economics and finance, No 512, 1-18. 1-10-2002. Stockholm of Economics, Centre for Health Economics. SSE/EFI working paper series in economics and finance, 2002b.
69. Zethraeus, N. & U. G. Gerdtham: Estimating the costs of hip fracture and potential savings. Int. J. Technol. Assess. Health Care 1998, 14, 255-267.
70. Zethraeus, N., L. Stromberg, B. Jonsson, O. Svensson & G. Ohlen: The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop. Scand. 1997, 68, 13-17.